Free shipping on all orders over $ 500


Cat. No. M10506
RK-33 Structure


Size Price Availability Quantity
2mg USD 80  USD80 In stock
5mg USD 140  USD140 In stock
10mg USD 256  USD256 In stock
25mg USD 442  USD442 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

RK-33 is a first-in-class, potent and selective DDX3 (RNA helicase) inhibitor, it binds to DDX3 and abrogates its activity. RK-33 caused G1 cell cycle arrest, induced apoptosis, and promoted radiation sensitization in DDX3-overexpressing cells. Inhibition of DDX3 by RK-33 also promotes tumor regression, thus providing a compelling argument to develop DDX3 inhibitors for lung cancer therapy. RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3.

Cell Experiment
Cell lines MDA-MB-231 cells
Preparation method Healthy, 60-70% confluent MDA-MB-231 cells are transduced with shDDX3 lentivirus particles. Knockdown of DDX3 expression is confirmed both by qRT-PCR and immunoblotting. MDA-MB-231 cells are treated with RK-33 (7.5 μM) for 12 h and harvested for RNA. Microarray experiments are performed.
Concentrations 7.5 μM
Incubation time 12 h
Animal Experiment
Animal models
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 428.44
Formula C23H20N6O3
CAS Number 1070773-09-9
Purity >99%
Solubility DMSO 30 mg/mL
Storage at -20°C

[1] Min Xie, et al. Cancer Res. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3

[2] Guus Martinus Bol, et al. Cancer Chemother Pharmacol. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3

[3] Guus M Bol, et al. EMBO Mol Med. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy

Related DNA/RNA Synthesis Products

TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity.


TH287 is a potent and selective inhibitor of MTH1, with an IC50 of 0.8 nM.

RG7800 hydrochloride

RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.


Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells.


O6-Benzylguanine, a guanine analog, is the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (MGMT/AGT) inhibitor.

Abmole Inhibitor Catalog

Keywords: RK-33, RK33 supplier, DNA/RNA Synthesis, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.